JAK/STAT Signaling Predominates in Human and Murine Fungal Post-infectious Inflammatory Response Syndrome

Jessica C Hargarten1, Kenneth Ssebambulidde1,2, Seher H Anjum1

  • 1Laboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.

Insights

Post-infection inflammatory response syndrome (PIIRS) involves JAK/STAT pathway activation. Inhibiting this pathway improved neurological damage markers and inflammatory cells in mice and humans.

Area of Science:

  • Neuroscience
  • Immunology
  • Infectious Diseases

Background:

  • Post-infection inflammatory syndromes (PIIRS) are a significant cause of host damage in various infections, including cryptococcal meningoencephalitis (CM).
  • Neurological infections pose unique challenges due to the skull's limited space, exacerbating inflammatory edema and damage.
  • PIIRS is a major mortality factor in non-HIV-infected cryptococcal meningoencephalitis.

Approach:

  • Investigated PIIRS using a murine model of cryptococcal meningoencephalitis.
  • Performed neurologic transcriptional pathway analysis to identify key molecular pathways involved in PIIRS.
  • Administered JAK/STAT inhibitors in both murine models and human patients with steroid-refractory PIIRS.

Key Points:

  • Murine model studies revealed predominant Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway activation in PIIRS.
  • JAK/STAT inhibitor treatment in mice reduced central nervous system (CNS) damage markers and specific inflammatory immune cells.
  • Human trials with ruxolitinib, a JAK/STAT inhibitor, demonstrated reduced inflammatory cells and improved brain imaging in PIIRS patients.
  • Treatment in humans was well-tolerated and offered a steroid-sparing approach for refractory cases.

Conclusions:

  • The JAK/STAT pathway plays a critical role in the pathogenesis of PIIRS.
  • JAK/STAT inhibitors show promise as an adjunctive therapy for PIIRS and other neurological inflammatory syndromes.
  • This research supports pathway-driven therapeutic strategies for managing severe post-infectious inflammatory conditions.